Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The prognosis of small cell lung cancer (SCLC) is still poor because of rapid recurrence, despite good response to initial chemotherapy. Additionally, patients’ old ages and comorbidities are often obstacles that make it difficult to apply subsequent treatment after initial treatment. This retrospective study analyzed the correlation of post-progression survival (PPS) with overall survival (OS), and prognostic factors including comorbidities to figure out impact of subsequent chemotherapy on OS in elderly extensive disease SCLC. Methods: We analyzed 101 patients of age 65 years or older who were recently diagnosed with extensive disease SCLC (ED-SCLC) in Korea University Medical Center between January 1995 and December 2015. The degree of comorbidity was scored using simplified comorbidity score (SCS). Correlation between PPS, progression-free survival (PFS) and OS was analyzed using a Pearson correlation coefficient. Cox proportional hazards regression was employed to examine the influence of clinical variables on survival. Results: Median age of patients was 71 years old (range, 65 to 83). Median OS was 8.7 months (range, 0.3 to 42.7). PPS was a reliable factor on OS than PFS (R2 = 0.852, p < 0.001). Prognostic factors associated with improved survival were SCS < 9, administration > 4 cycles of first line chemotherapy and subsequent second line chemotherapy. Conclusions: PPS was more correlated with OS than PFS in elderly patients with ED-SCLC. The most important prognostic factors for PPS and OS included SCS and second line chemotherapy. Patients receiving subsequent treatment had increased OS regardless of degree of comorbidity.
Abstract
Background/Aims: The prognosis of small cell lung cancer (SCLC) is still poor because of rapid recurrence, despite good response to initial chemotherapy. Additionally, patients’ old ages and comorbidities are often obstacles that make it difficult to apply subsequent treatment after initial treatment. This retrospective study analyzed the correlation of post-progression survival (PPS) with overall survival (OS), and prognostic factors including comorbidities to figure out impact of subsequent chemotherapy on OS in elderly extensive disease SCLC. Methods: We analyzed 101 patients of age 65 years or older who were recently diagnosed with extensive disease SCLC (ED-SCLC) in Korea University Medical Center between January 1995 and December 2015. The degree of comorbidity was scored using simplified comorbidity score (SCS). Correlation between PPS, progression-free survival (PFS) and OS was analyzed using a Pearson correlation coefficient. Cox proportional hazards regression was employed to examine the influence of clinical variables on survival. Results: Median age of patients was 71 years old (range, 65 to 83). Median OS was 8.7 months (range, 0.3 to 42.7). PPS was a reliable factor on OS than PFS (R2 = 0.852, p < 0.001). Prognostic factors associated with improved survival were SCS < 9, administration > 4 cycles of first line chemotherapy and subsequent second line chemotherapy. Conclusions: PPS was more correlated with OS than PFS in elderly patients with ED-SCLC. The most important prognostic factors for PPS and OS included SCS and second line chemotherapy. Patients receiving subsequent treatment had increased OS regardless of degree of comorbidity.
참고문헌 (32)
- Siegel RL, "Cancer statistics, 2018", CA Cancer J Clin, 68, pp.7~30 (2018)
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2017", Cancer Research and Treatment, 49(2), pp.306~312 (2017), 대한암학회
- Jackman DM, "Small-cell lung cancer", Lancet, 366, pp.1385~1396 (2005)
- Janne PA, "Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America", Cancer, 95, pp.1528~1538 (2002)
- Chute JP, "Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer : perceptible progress", J Clin Oncol, 17, pp.1794~1801 (1999)
- Hotta K, "Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer : a systematic review", PLoS One, 6, pp.e26646~ (2011)
- Saad ED, "Overall survival and post-progression survival in advanced breast cancer : a review of recent randomized clinical trials", J Clin Oncol, 28, pp.1958~1962 (2010)
- Sundar S, "A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer", Gynecol Oncol, 125, pp.493~499 (2012)
- Colinet B, "A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index", Br J Cancer, 93, pp.1098~1105 (2005)
- Jacot W, "Quality of life and comorbidity score as prognostic determinants in non-smallcell lung cancer patients", Ann Oncol, 19, pp.1458~1464 (2008)
- Kuo YW, "The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma", J Thorac Oncol, 6, pp.378~383 (2011)
- Kalemkerian GP, "NCCN guidelines insights : small cell lung cancer, version 2. 2018", J Natl Compr Canc Netw, 16, pp.1171~1182 (2018)
- Micke P, "Staging small cell lung cancer : Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer : what limits limited disease", Lung Cancer, 37, pp.271~276 (2002)
- Imai H, "Clinical significance of post-progression survival in lung cancer", Thorac Cancer, 8, pp.379~386 (2017)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Broglio KR, "Detecting an overall survival benefit that is derived from progression-free survival", J Natl Cancer Inst, 101, pp.1642~1649 (2009)
- Soria JC, "Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy", Ann Oncol, 21, pp.2324~2332 (2010)
- Reck M, "Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer : AVAil", J Clin Oncol, 27, pp.1227~1234 (2009)
- Petrelli F, "Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer", Ann Oncol, 24, pp.186~192 (2013)
- Hayashi H, "Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer", Ann Oncol, 23, pp.1537~1541 (2012)
- 김효정, "Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib", Journal of Korean Medical Science, 28(11), pp.1595~1602 (2013), 대한의학회
- Kasahara N, "Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy", Radiol Oncol, 49, pp.409~415 (2015)
- Imai H, "Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer", Ann Thorac Med, 10, pp.61~66 (2015)
- Imai H, "Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer", Thorac Cancer, 7, pp.655~662 (2016)
- Imai H, "Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer", Neoplasma, 61, pp.233~240 (2014)
- Yoshino R, "Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer", J Cancer Res Ther, 11, pp.606~611 (2015)
- Antonia SJ, "Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer(CheckMate 032) : a multicentre, open-label, phase 1", 2 trial, 2016, pp.17, 883~895
- Horn L, "First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer", N Engl J Med, 379, pp.2220~2229 (2018)
- Lallo A, "The aombination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer", Clin Cancer Res, 24, pp.5153~5164 (2018)
- Lashari BH, "Rovalpituzumab tesirine : a novel DLL3-targeting antibody-drug conjugate", Drugs R D, 18, pp.255~258 (2018)
- Lochmann TL, "BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer", Oncoscience, 5, pp.218~219 (2018)
- Ball D, "Evaluation of the simplified comorbidity score (Colinet) as a prognostic indicator for patients with lung cancer: a cancer registry study", Lung Cancer, 82, pp.358~361 (2013)